Silver Book Fact

High-intensity ultrasonic cyclocoagulation reduces intraocular pressure in refractory glaucoma patients.

Aptel F, Charrell T, Lafon C, Ramano F, et al. Miniaturized High-Intensity Focused Ultrasound Device in Patients with Glaucoma: A clinical pilot study. Invest Opthalmol Vis Sci. 2011; 52(12): 8747-8753. http://iovs.arvojournals.org/article.aspx?articleid=2187000

Reference

Title
Miniaturized High-Intensity Focused Ultrasound Device in Patients with Glaucoma: A clinical pilot study
Publication
Invest Opthalmol Vis Sci
Publication Date
2011
Authors
Aptel F, Charrell T, Lafon C, Ramano F, et al
Volume & Issue
Volume 52, Issue 12
Pages
8747-8753
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Of the 8 million older Americans at high risk of developing advanced age-related macular degeneration (AMD), 1.3 million will develop advanced AMD within 5 years. However, the NEI-sponsored Age-Related Eye…  
  • DR Treatment Savings in the US
    Every year, the U.S. saves an estimated $1.6 billion by treating DR.  
  • Anti-VEGF Visual Improvement
    Nearly 50% of DME patients who received an anti-VEGF drug, experienced substantial visual improvement after a year of injections.  
  • Gene transfer process treatment for diabetic retinopathy
    A gene transfer process that produces a VEGF receptor prevents retinal vascular permeability (RVP) associated with diabetes that could have value in treating diabetic retinopathy.  
  • Macugen to treat wet age-related macular degeneration (AMD)
    A new FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)– pegaptanib sodium (Macugen)– reduced vision loss in 70% of clinical trial patients.